FDA-cleared profile

Rapid ASPECTS (v3)

iSchemaView, Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Adjunct assessment of early ischemic brain tissue injury and extent of disease in adult ischemic-stroke diagnostic imaging workup, typically within 24 hours of last known well

Clinical role
Concurrent CADx adjunct: presents original and annotated images, atlas ROIs, and numerical scoring for clinician review and verification; it is not the primary interpretation
Images and patients
CT/CTA · Brain/head ASPECTS regions
Key limitation
Keep in mind: Use only for ischemic stroke following standard of care; adjunct only and not a replacement for original-image review or clinical judgment; do not use CAD output as the primary interpretation; exclude technically inadequate motion, hemorrhagic transformation or hematoma, and very thin or absent ventricles

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Adjunct assessment of early ischemic brain tissue injury and extent of disease in adult ischemic-stroke diagnostic imaging workup, typically within 24 hours of last known well
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain/head ASPECTS regions Input: NCCT brain image data from adult patients presenting for diagnostic imaging workup; Rapid uses DICOM-compatible Rapid/PACS workflow and the ASPECTS processing pipeline
  • Who uses it?Intended users: Clinicians and medical imaging professionals, including neuroradiologists and other physicians; the reader study represented neurology, radiology, emergency medicine, and neurocritical care readers
  • What does the software produce?Output: Automatic ASPECTS score with identified and highlighted atlas regions, numerical scoring, and overlays for early ischemic change and prior stroke areas; the clinician may review/edit the result before sending the score, selected regions, and underlying values to PACS or a workstation
  • What is its most important limitation?Key limitation: Use only for ischemic stroke following standard of care; adjunct only and not a replacement for original-image review or clinical judgment; do not use CAD output as the primary interpretation; exclude technically inadequate motion, hemorrhagic transformation or hematoma, and very thin or absent ventricles

Clinical takeaway. Clinical role: Adjunct assessment of early ischemic brain tissue injury and extent of disease in adult ischemic-stroke diagnostic imaging workup, typically within 24 hours of last known well

Evidence takeaway. Evidence from the reviewed source record: The FDA packet reports standalone performance on 88 cases and reader-improvement analysis on 102 scans. Standalone percent agreement with the reference at both region and scan level was 82.8%. In the reader study, agreement with the reference increased from 82% to 84% excluding the expert, and average agreement increased from 80.4% to 83.3% with assistance. A supplemental confounder set changed 3 of 115 reads (2.6%).

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Adjunct assessment of early ischemic brain tissue injury and extent of disease in adult ischemic-stroke diagnostic imaging workup, typically within 24 hours of last known well
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Concurrent CADx adjunct: presents original and annotated images, atlas ROIs, and numerical scoring for clinician review and verification; it is not the primary interpretation
  • Exact FDA submission
  • Checked 2026-09-08
Required input
NCCT brain image data from adult patients presenting for diagnostic imaging workup; Rapid uses DICOM-compatible Rapid/PACS workflow and the ASPECTS processing pipeline
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
Automatic ASPECTS score with identified and highlighted atlas regions, numerical scoring, and overlays for early ischemic change and prior stroke areas; the clinician may review/edit the result before sending the score, selected regions, and underlying values to PACS or a workstation
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Acute ischemic-stroke diagnostic imaging, including community hospitals and primary stroke centers and acute work in comprehensive centers as described in the FDA risk-benefit discussion
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Clinicians and medical imaging professionals, including neuroradiologists and other physicians; the reader study represented neurology, radiology, emergency medicine, and neurocritical care readers
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Use only for ischemic stroke following standard of care; adjunct only and not a replacement for original-image review or clinical judgment; do not use CAD output as the primary interpretation; exclude technically inadequate motion, hemorrhagic transformation or hematoma, and very thin or absent ventricles
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
The FDA packet reports standalone performance on 88 cases and reader-improvement analysis on 102 scans. Standalone percent agreement with the reference at both region and scan level was 82.8%. In the reader study, agreement with the reference increased from 82% to 84% excluding the expert, and average agreement increased from 80.4% to 83.3% with assistance. A supplemental confounder set changed 3 of 115 reads (2.6%).
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The FDA packet reports standalone performance on 88 cases and reader-improvement analysis on 102 scans. Standalone percent agreement with the reference at both region and scan level was 82.8%. In the reader study, agreement with the reference increased from 82% to 84% excluding the expert, and average agreement increased from 80.4% to 83.3% with assistance. A supplemental confounder set changed 3 of 115 reads (2.6%).
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
83.3%
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-13

Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Rapid ASPECTS (v3) regulatory performance study summary

  • DesignStand-alone performance and reader study (ACR AI Central category)
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K232156
  • Samplen=88
  • IndependenceIndependence not established

K232156

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K232156. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: NCCT brain image data from adult patients presenting for diagnostic imaging workup; Rapid uses DICOM-compatible Rapid/PACS workflow and the ASPECTS processing pipeline

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K232156: Rapid ASPECTS (v3)

  2. Routing

    Source context, not route validation: Rapid can run within the Rapid Platform on a customer server or online virtual system, receives/processes image data through the PACS/Rapid workflow, and sends the final score and regional data to PACS or a workstation using DICOM-related interoperability

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K232156: Rapid ASPECTS (v3)

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. A legacy catalog deployment category, normalized to fixed categories, was not traced to the exact FDA decision document it cited, so it is not published as verified. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor or an exact-submission source that states it.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-13 ·

  4. Returned objects

    Source context, not route validation: Automatic ASPECTS score with identified and highlighted atlas regions, numerical scoring, and overlays for early ischemic change and prior stroke areas; the clinician may review/edit the result before sending the score, selected regions, and underlying values to PACS or a workstation

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K232156: Rapid ASPECTS (v3)

  5. Viewer/worklist/report

    Unresolved route: Automatic ASPECTS score with identified and highlighted atlas regions, numerical scoring, and overlays for early ischemic change and prior stroke areas; the clinician may review/edit the result before sending the score, selected regions, and underlying values to PACS or a workstation

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K232156: Rapid ASPECTS (v3)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
Rapid can run within the Rapid Platform on a customer server or online virtual system, receives/processes image data through the PACS/Rapid workflow, and sends the final score and regional data to PACS or a workstation using DICOM-related interoperability
  • Exact FDA submission
  • Checked 2026-09-08
Security
RapidAI's current platform security and compliance one-pager states that its portfolio uses encryption at rest and in transit, role-based access control, monitoring/logging and listed HIPAA, GDPR, ISO 13485, ISO 27001, ISO 27701 and SOC 2 Type 1 claims.
  • Vendor-wide
  • Checked 2026-10-25

This is a current vendor-wide statement, not an independent attestation for the exact K223396 release; site-specific architecture, retention, contractual scope and current certification evidence remain unestablished.

Monitoring
RapidAI's security and compliance one-pager (Rev 8, published by iSchemaView, Inc.) states continuous infrastructure monitoring and system telemetry to detect operational anomalies in real time, plus a formal incident response and escalation framework with defined communication protocols.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. No certificate or audit report was read; the one-pager names the RapidAI platform generally and does not scope these commitments to any specific product release; exact-release scope is not established.

Result destination

PACS is explicitly referenced as a result destination.

exact submission · checked 2026-09-01

Confirm supported products, versions, routing behavior, and display requirements during local evaluation.

Supported acquisition environment

Scanner manufacturers: GE

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Rapid ASPECTS (v3); FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K232156
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Brain/head ASPECTS regions
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-01-19
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
10Source classes checked
12Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 12 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 12 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor security document, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K232156 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not verified - checked 2026-11-13 - Exact FDA submission

    A legacy catalog deployment category, normalized to fixed categories, was not traced to the exact FDA decision document it cited, so it is not published as verified. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor or an exact-submission source that states it.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

9 sources - 3 history items

Source ledger

  1. FDA K232156: Rapid ASPECTS (v3)

    U.S. Food and Drug Administration - Published 2024-01-19 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Rapid ASPECTS (v3) model card (K232156)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, limitations, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. RapidAI security and compliance one-pager

    RapidAI - Accessed 2026-09-08

    Scope: vendorWideSecurity, deployment, implementationCapabilities

  8. openFDA exact recall query for K232156

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

  9. RapidAI security and compliance one-pager (Rev 8)

    iSchemaView, Inc. (RapidAI) - Accessed 2026-10-27

    Scope: security, monitoring

Research history

  1. K232156 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K200760

Rapid ASPECTS

iSchemaView Inc.

Authorized purpose: Adjunct evaluation of extent of early ischemic brain injury in patients with known MCA or ICA occlusion during stroke imaging interpretation within 6 hours

Modality
CT/CTA
Anatomy
Brain/head ASPECTS regions
Decision
2020-06-26
FDA-cleared K252421

JLK-NCCT

JLK, Inc.

Authorized purpose: Notification-only triage of adult non-contrast head CT for suspected intracranial hemorrhage and large-vessel occlusion, with parallel communication to trained clinicians during standard care.

Modality
CT/CTA
Anatomy
Brain and intracranial vessels: intracranial hemorrhage and LVO involving ICA, MCA-M1, and MCA-M2
Decision
2026-03-24
FDA-cleared K251983

Brainomix 360 Triage Stroke

Brainomix Limited

Authorized purpose: Triage and notification of suspected intracranial hemorrhage or anterior-circulation LVO on acute non-contrast head CT; not primary diagnosis.

Modality
CT/CTA
Anatomy
Brain/head, including intracranial ICA and M1 for LVO and intracranial hemorrhage findings
Decision
2025-08-26

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history